

Teuvo L J Tammela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4085486/publications.pdf>

Version: 2024-02-01

191
papers

11,344
citations

81900

39
h-index

31849

101
g-index

195
all docs

195
docs citations

195
times ranked

14392
citing authors

#	ARTICLE	IF	CITATIONS
1	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nature Genetics</i> , 1995, 9, 401-406.	21.4	1,316
2	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014, 384, 2027-2035.	13.7	1,261
3	Overdiagnosis and Overtreatment of Prostate Cancer. <i>European Urology</i> , 2014, 65, 1046-1055.	1.9	709
4	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
5	Evidence for a prostate cancer susceptibility locus on the X chromosome.. <i>Nature Genetics</i> , 1998, 20, 175-179.	21.4	641
6	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1235-1246.	27.0	621
7	Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2859-2859.	1.6	439
8	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	21.4	408
9	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019, 76, 43-51.	1.9	359
10	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAİL Study. <i>European Urology</i> , 2017, 71, 151-154.	1.9	306
11	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
12	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020, 383, 1040-1049.	27.0	225
13	What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women. <i>European Urology</i> , 2014, 65, 1211-1217.	1.9	193
14	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. <i>Lancet Oncology, The</i> , 2014, 15, 975-985.	10.7	172
15	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
16	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	1.9	131
17	Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. <i>Cell</i> , 2018, 174, 576-589.e18.	28.9	116
18	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. <i>European Urology</i> , 2015, 68, 885-890.	1.9	111

#	ARTICLE	IF	CITATIONS
19	Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS). <i>European Urology</i> , 2015, 67, 482-491.	1.9	106
20	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017, 19, 2045-2059.	6.4	99
21	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
22	Endocrine treatment of prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2004, 92, 287-295.	2.5	84
23	Detection of Prostate Cancer by an Electronic Nose: A Proof of Principle Study. <i>Journal of Urology</i> , 2014, 192, 230-235.	0.4	72
24	The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth. <i>PLoS ONE</i> , 2012, 7, e39445.	2.5	69
25	Transcriptome Sequencing Reveals <i>PCAT5</i> as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. <i>Cancer Research</i> , 2015, 75, 4026-4031.	0.9	68
26	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , 2019, 76, 586-595.	1.9	68
27	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	2.9	67
28	Priapism, its Incidence and Seasonal Distribution in Finland. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995, 29, 93-96.	1.4	65
29	Insulin-Like Growth Factor I Is Not a Useful Marker of Prostate Cancer in Men with Elevated Levels of Prostate-Specific Antigen. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2744-2747.	3.6	63
30	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. <i>British Journal of Cancer</i> , 2018, 119, 347-356.	6.4	63
31	Androgen receptor CAG polymorphism and prostate cancer risk. <i>Human Genetics</i> , 2002, 111, 166-171.	3.8	61
32	Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. <i>Targeted Oncology</i> , 2019, 14, 527-539.	3.6	60
33	Benign Prostatic Hyperplasia. <i>Drugs and Aging</i> , 1997, 10, 349-366.	2.7	59
34	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	2.3	54
35	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	12.8	50
36	Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy—A Randomized, Double-blind, Placebo-controlled Clinical Trial. <i>European Urology</i> , 2018, 74, 697-701.	1.9	50

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. <i>European Urology</i> , 2016, 69, 834-840.	1.9	49
38	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 73, 870-876.	1.9	44
39	Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). <i>European Urology</i> , 2016, 69, 720-727.	1.9	41
40	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 5-12.	1.0	41
41	Preservation of Potency after Treatment for Priapism. <i>Scandinavian Journal of Urology and Nephrology</i> , 1996, 30, 313-316.	1.4	40
42	Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. <i>Cancer Medicine</i> , 2015, 4, 1417-1425.	2.8	39
43	Prostate cancer risk prediction using a polygenic risk score. <i>Scientific Reports</i> , 2020, 10, 17075.	3.3	39
44	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 17978.	3.3	38
45	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	5.4	38
46	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. <i>Human Genetics</i> , 2016, 135, 923-938.	3.8	37
47	Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 212-220.	3.1	37
48	Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time. <i>Clinical Epidemiology</i> , 2019, Volume 11, 923-932.	3.0	37
49	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. <i>European Journal of Epidemiology</i> , 2017, 32, 521-527.	5.7	36
50	Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). <i>Journal of Clinical Oncology</i> , 2020, 38, 5514-5514.	1.6	36
51	Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. <i>Clinical Cancer Research</i> , 2016, 22, 243-249.	7.0	35
52	Rapid and Accurate Detection of Urinary Pathogens by Mobile IMS-Based Electronic Nose: A Proof-of-Principle Study. <i>PLoS ONE</i> , 2014, 9, e114279.	2.5	35
53	Urothelial permeability of the isolated whole bladder. <i>Neurourology and Urodynamics</i> , 1993, 12, 39-47.	1.5	33
54	ANO7 is associated with aggressive prostate cancer. <i>International Journal of Cancer</i> , 2018, 143, 2479-2487.	5.1	31

#	ARTICLE	IF	CITATIONS
55	Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. <i>Scandinavian Journal of Urology</i> , 2016, 50, 267-273.	1.0	30
56	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFORS Trials. <i>European Urology Focus</i> , 2018, 4, 547-553.	3.1	30
57	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0150241.	2.5	28
58	Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 66-76.	3.9	28
59	Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. <i>Journal of Urology</i> , 2019, 201, 486-495.	0.4	28
60	Genome-Wide Association Study of Prostate Cancer-specific Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1796-1800.	2.5	27
61	Association of Dietary Elements and Lower Urinary Tract Symptoms. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 46-50.	1.4	26
62	Six-year follow-up and predictors of urgency-associated urinary incontinence and bowel symptoms among the oldest old: A population-based study. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, e85-e90.	3.0	24
63	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 50-57.	0.4	24
64	Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. <i>European Journal of Cancer</i> , 2021, 154, 138-146.	2.8	24
65	The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study. <i>Cancer Causes and Control</i> , 2011, 22, 1445-1452.	1.8	23
66	Endocrine prevention and treatment of prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 59-67.	3.2	23
67	Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon- γ 2a in Reducing Recurrence of Non-muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. <i>European Urology</i> , 2016, 70, 341-347.	1.9	23
68	Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 481, 46-50.	2.1	23
69	Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. <i>Oncotarget</i> , 2015, 6, 6235-6250.	1.8	23
70	Bladder Cancer Survival of Men Receiving 5 α -Reductase Inhibitors. <i>Journal of Urology</i> , 2018, 200, 743-748.	0.4	22
71	Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. <i>International Journal of Cancer</i> , 2015, 137, 1187-1195.	5.1	21
72	Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. <i>European Journal of Cancer Care</i> , 2018, 27, e12729.	1.5	21

#	ARTICLE	IF	CITATIONS
73	Duration of increased mucosal permeability of the urinary bladder after acute overdistension: an experimental study in rats. <i>Urological Research</i> , 1999, 27, 272-276.	1.5	20
74	Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 372-381.	1.9	20
75	The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines. <i>European Journal of Pharmacology</i> , 2016, 788, 160-167.	3.5	20
76	Seeking certainty through narrative closure: men's stories of prostate cancer treatments in a state of liminality. <i>Sociology of Health and Illness</i> , 2018, 40, 639-653.	2.1	20
77	Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial. <i>Prostate</i> , 2015, 75, 1394-1402.	2.3	19
78	A genetic variant near <i>GATA3</i> implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). <i>Prostate</i> , 2017, 77, 1213-1220.	2.3	19
79	Bacterial adherence to silver nitrate coated poly- L -lactic acid urological stents in vitro. <i>Urological Research</i> , 2000, 28, 327-331.	1.5	18
80	Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. <i>European Journal of Cancer</i> , 2015, 51, 1283-1292.	2.8	18
81	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. <i>European Urology Focus</i> , 2017, 3, 606-614.	3.1	18
82	Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. <i>PLoS ONE</i> , 2016, 11, e0153413.	2.5	18
83	Statin use and risk of disease recurrence and death after radical prostatectomy. <i>Prostate</i> , 2016, 76, 469-478.	2.3	17
84	Synergistic Interaction of <i>HOXB13</i> and <i>CIP2A</i> Predisposes to Aggressive Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6265-6276.	7.0	17
85	Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. <i>Genes</i> , 2020, 11, 314.	2.4	16
86	Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5000-5000.	1.6	16
87	Amplification of the 9p13.3 chromosomal region in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 617-625.	2.8	14
88	5 α - α reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. <i>International Journal of Cancer</i> , 2016, 138, 2820-2828.	5.1	14
89	Germline copy number variation analysis in Finnish families with hereditary prostate cancer. <i>Prostate</i> , 2016, 76, 316-324.	2.3	14
90	Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Cancer Epidemiology</i> , 2016, 45, 1-5.	1.9	14

#	ARTICLE	IF	CITATIONS
91	Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2016, 50, 413-419.	1.0	14
92	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020, 28, 1467-1475.	2.8	14
93	Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. <i>Cancer Causes and Control</i> , 2016, 27, 637-645.	1.8	13
94	Expression and ERG regulation of PIM kinases in prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 3427-3436.	2.8	13
95	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study. <i>BJU International</i> , 2022, 130, 193-199.	2.5	13
96	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. <i>PLoS ONE</i> , 2020, 15, e0234269.	2.5	12
97	Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. <i>EBioMedicine</i> , 2021, 68, 103432.	6.1	12
98	Malignant Fibrous Histiocytoma of the Prostate. <i>Scandinavian Journal of Urology and Nephrology</i> , 1994, 28, 429-431.	1.4	11
99	Cytotoxicity testing of a new caprolactone-coated self-expanding bioabsorbable self-reinforced poly-l-lactic acid urethral stent. <i>Urological Research</i> , 1999, 27, 149-152.	1.5	11
100	High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. <i>Scandinavian Journal of Urology</i> , 2017, 51, 367-372.	1.0	11
101	Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 453-460.	3.9	11
102	Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 317-323.	3.9	11
103	A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5001-5001.	1.6	11
104	CYP1A1 activity in renal cell carcinoma and in adjacent normal renal tissue. <i>Urological Research</i> , 1998, 26, 117-121.	1.5	10
105	Components of metabolic syndrome and prognosis of renal cell cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 435-441.	1.0	10
106	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. <i>Cancer Imaging</i> , 2020, 20, 72.	2.8	10
107	Influence of Transient Overdistension on Bladder Wall Morphology and Enzyme Histochemistry. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997, 31, 517-522.	1.4	9
108	PREDICTORS OF BIOLOGICAL AGGRESSIVENESS OF PROSTATE SPECIFIC ANTIGEN SCREENING DETECTED PROSTATE CANCER. <i>Journal of Urology</i> , 2001, 165, 1569-1574.	0.4	9

#	ARTICLE	IF	CITATIONS
109	MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families. <i>PLoS ONE</i> , 2015, 10, e0127427.	2.5	9
110	Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 544.e25-544.e31.	1.6	9
111	Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. <i>BMC Cancer</i> , 2017, 17, 585.	2.6	9
112	Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 321-327.	1.0	9
113	Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. <i>International Journal of Clinical Oncology</i> , 2021, 26, 578-590.	2.2	9
114	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. <i>European Urology Oncology</i> , 2021, 4, 49-55.	5.4	9
115	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic <i>TMPRSS2:ERG</i> fusion status. <i>Human Molecular Genetics</i> , 2016, 25, ddw349.	2.9	8
116	The effect of nonsteroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. <i>Prostate</i> , 2017, 77, 1029-1035.	2.3	8
117	Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2018, 52, 269-276.	1.0	8
118	Factors related to self-rated health and life satisfaction one year after radical prostatectomy for localised prostate cancer: a cross-sectional survey. <i>Scandinavian Journal of Caring Sciences</i> , 2019, 33, 688-697.	2.1	8
119	Elevated post-void residual volume in a geriatric post-hip fracture assessment in women-associated factors and risk of mortality. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 75-83.	2.9	8
120	A Four-kallikrein Panel and β 2-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 561-567.	3.1	8
121	Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial. <i>Scandinavian Journal of Urology</i> , 2021, 55, 348-353.	1.0	8
122	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. <i>Journal of Medical Screening</i> , 2013, 20, 33-38.	2.3	8
123	Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis. <i>PLoS ONE</i> , 2014, 9, e89508.	2.5	7
124	Natural Course of Lower Urinary Tract Symptoms in Men Not Requiring Treatment—A 5-Year Longitudinal Population-based Study. <i>Urology</i> , 2014, 83, 411-415.	1.0	7
125	Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. <i>European Urology</i> , 2015, 68, 1089-1097.	1.9	7
126	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. <i>Journal of Urology</i> , 2017, 198, 1333-1339.	0.4	7

#	ARTICLE	IF	CITATIONS
127	Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 373-378.	3.9	7
128	Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. <i>European Urology</i> , 2019, 75, 1015-1022.	1.9	7
129	The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). <i>Clinical Cancer Research</i> , 2019, 25, 839-843.	7.0	7
130	Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	1.6	7
131	Biocompatibility of silver nitrate and ofloxacin coated bioabsorbable SR-PLLA rods. <i>Urological Research</i> , 2001, 29, 113-117.	1.5	6
132	Muraglitazar-Eluting Bioabsorbable Vascular Stent Inhibits Neointimal Hyperplasia in Porcine Iliac Arteries. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 124-130.	0.5	6
133	Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men. <i>Urology</i> , 2016, 95, 164-170.	1.0	6
134	Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. <i>European Urology</i> , 2016, 70, 499-505.	1.9	6
135	Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 483-490.	3.9	6
136	Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. <i>PLoS ONE</i> , 2019, 14, e0224479.	2.5	6
137	Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer. <i>Cancer Causes and Control</i> , 2021, 32, 1299-1313.	1.8	6
138	Outcomes of Screening for Prostate Cancer Among Men Who Use Statins. <i>JAMA Oncology</i> , 2022, 8, 61.	7.1	6
139	Lower Urinary Tract Symptoms and Mortality among Finnish Men: The Roles of Symptom Severity and Bother. <i>Journal of Urology</i> , 2022, 207, 1285-1294.	0.4	6
140	Modeling and Analysis of Gleason Score 8-10 Prostate Cancers in the REDUCE Study. <i>Urology</i> , 2014, 84, 393-399.	1.0	5
141	Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies <i>DCAT2</i> as a new target gene. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 661-673.	2.8	5
142	Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. <i>European Urology Focus</i> , 2018, 4, 851-857.	3.1	5
143	Risk of urothelial cancer death among people using antihypertensive drugs—a cohort study from Finland. <i>Scandinavian Journal of Urology</i> , 2019, 53, 185-192.	1.0	5
144	Prevalence of autoimmune disorders among bladder pain syndrome patients' relatives. <i>Scandinavian Journal of Urology</i> , 2021, 55, 72-77.	1.0	5

#	ARTICLE	IF	CITATIONS
145	Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease. Prostate Cancer and Prostatic Diseases, 2021, 24, 1158-1166.	3.9	5
146	ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2019, 37, 140-140.	1.6	5
147	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open, 2022, 12, e050264.	1.9	5
148	Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. European Journal of Cancer, 2018, 93, 108-118.	2.8	4
149	Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. Cancer Medicine, 2020, 9, 5643-5654.	2.8	4
150	AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene, 2020, 39, 5241-5251.	5.9	4
151	Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cancer, 2021, 127, 188-192.	4.1	4
152	Sauna habits/bathing and changes in lower urinary tract symptoms â€” Tampere Ageing Male Urologic Study (TAMUS). Scandinavian Journal of Urology, 2022, 56, 77-82.	1.0	4
153	What explains the differences between centres in the European screening trial? A simulation study. Cancer Epidemiology, 2017, 46, 14-19.	1.9	3
154	Outcomes of Prostate Cancer Screening by 5 α -Reductase Inhibitor Use. Journal of Urology, 2017, 198, 305-309.	0.4	3
155	Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. International Journal of Cancer, 2019, 145, 632-638.	5.1	3
156	Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. European Urology Focus, 2019, 5, 186-191.	3.1	3
157	Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers, 2021, 13, 435.	3.7	3
158	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. European Urology Focus, 2021, , .	3.1	3
159	Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.. Journal of Clinical Oncology, 2021, 39, 239-239.	1.6	3
160	Antidiabetic Drugs and Prostate Cancer Prognosis in a Finnish Population-Based Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 982-989.	2.5	3
161	Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. International Journal of Cancer, 2021, 149, 307-315.	5.1	3
162	Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. Journal of Clinical Oncology, 2021, 39, 5079-5079.	1.6	3

#	ARTICLE	IF	CITATIONS
163	A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 115-115.	1.6	3
164	Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level. Cancers, 2022, 14, 2920.	3.7	3
165	Effect of Concomitant Administration of Clodronate and Estramustine Phosphate on their Bioavailability in Patients with Metastasized Prostate Cancer. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 157-160.	0.0	2
166	Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. Scientific Reports, 2018, 8, 10308.	3.3	2
167	The expanded prostate cancer index composite short form (EPIC-26) for measuring health-related quality of life: content analysis of patients' spontaneous comments written in survey margins. Quality of Life Research, 2021, , 1.	3.1	2
168	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European Urology Open Science, 2021, 30, 47-62.	0.4	2
169	Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.. Journal of Clinical Oncology, 2015, 33, 230-230.	1.6	2
170	Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system. Cancer Causes and Control, 2022, 33, 313-320.	1.8	2
171	Severity and bother of lower urinary tract symptoms among men aged 30-80 years: Tampere Ageing Male Urological Study (TAMUS). Scandinavian Journal of Urology, 2018, 52, 296-301.	1.0	1
172	Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. Annals of Diagnostic Pathology, 2018, 35, 80-84.	1.3	1
173	Seasonal changes in occurrence and severity of lower urinary tract symptoms in Tampere Aging Male Urologic Study (TAMUS). LUTS: Lower Urinary Tract Symptoms, 2021, 13, 216-223.	1.3	1
174	Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.. Journal of Clinical Oncology, 2021, 39, 240-240.	1.6	1
175	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1
176	Long-term survival update of the Scandinavian Prostate Cancer Group 6 study: Bicalutamide 150 mg daily versus placebo in hormone-naïve, non-metastatic prostate cancer.. Journal of Clinical Oncology, 2015, 33, 2-2.	1.6	1
177	ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, TPS5094-TPS5094.	1.6	1
178	Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer. European Urology Open Science, 2021, 34, 27-32.	0.4	1
179	Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer. British Journal of Cancer, 2022, , .	6.4	1
180	ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2015, 33, TPS5080-TPS5080.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.. Journal of Clinical Oncology, 2016, 34, e16599-e16599.	1.6	0
182	Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial.. Journal of Clinical Oncology, 2018, 36, 30-30.	1.6	0
183	Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, 90-90.	1.6	0
184	Title is missing!. , 2019, 14, e0224479.		0
185	Title is missing!. , 2019, 14, e0224479.		0
186	Title is missing!. , 2019, 14, e0224479.		0
187	Title is missing!. , 2019, 14, e0224479.		0
188	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
189	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
190	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0
191	Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. , 2020, 15, e0234269.		0